Association between blood eosinophil count and risk of readmission for patients with asthma : Historical cohort study by Kerkhof, Marjan et al.
RESEARCH ARTICLE
Association between blood eosinophil count
and risk of readmission for patients with
asthma: Historical cohort study
Marjan Kerkhof1, Trung N. Tran2, Maarten van den Berge3, Guy G. Brusselle4,
Gokul Gopalan2, Rupert C. M. Jones5, Janwillem W. H. Kocks1,3, Andrew Menzies-Gow6,
Javier Nuevo7, Ian D. Pavord8, Sarang Rastogi2, David B. Price1,9*
1 Observational & Pragmatic Research Institute Pte Ltd, Singapore, Singapore, 2 AstraZeneca,
Gaithersburg, MD, United States of America, 3 University of Groningen, University Medical Center
Groningen, Groningen, Netherlands, 4 Ghent University Hospital, Ghent, Belgium, 5 The Peninsula College
of Medicine and Dentistry, Plymouth, United Kingdom, 6 Royal Brompton and Harefield NHS Foundation
Trust, London, United Kingdom, 7 AstraZeneca, Madrid, Spain, 8 Respiratory Medicine Unit and Oxford
Respiratory NIHR BRC, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom,
9 Academic Primary Care, University of Aberdeen, Aberdeen, United Kingdom
* dprice@opri.sg
Abstract
Background
Recent studies have demonstrated an association between high blood eosinophil counts
and greater risk of asthma exacerbations. We sought to determine whether patients hospi-
talized for an asthma exacerbation were at greater risk of readmission if they had a high
blood eosinophil count documented before the first hospitalization.
Methods
This historical cohort study drew on 2 years of medical record data (Clinical Practice
Research Datalink with Hospital Episode Statistics linkage) of patients (aged5 years)
admitted to hospital in England for asthma, with recorded blood eosinophil count within 1
baseline year before admission. We analyzed the association between high blood eosino-
phil count (0.35x109 cells/L) and readmission risk during 1 year of follow-up after hospital
discharge, with adjustment for predefined, relevant confounders using forward selection.
Results
We identified 2,613 eligible patients with asthma-related admission, of median age 51 years
(interquartile range, 36–69) and 76% women (1,997/2,613). Overall, 835/2,613 (32.0%) had
a preadmission high blood eosinophil count. During the follow-up year, 130/2,613 patients
(5.0%) were readmitted for asthma, including 55/835 (6.6%) with vs. 75/1,778 (4.2%) with-
out high blood eosinophil count at baseline (adjusted hazard ratio [HR] 1.49; 95% CI 1.04–
2.13, p = 0.029). The association was strongest in never-smokers (n = 1,296; HR 2.16, 95%
CI 1.27–3.68, p = 0.005) and absent in current smokers (n = 547; HR 1.00, 95% CI 0.49–
2.04, p = 0.997).
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Conclusions
A high blood eosinophil count in the year before an asthma-related hospitalization is associ-
ated with increased risk of readmission within the following year. These findings suggest
that patients with asthma and preadmission high blood eosinophil count require careful fol-
low-up, with treatment optimization, after discharge.
Introduction
Severe asthma exacerbations may result in hospital admissions, relatively rare but important
events with adverse implications for patients’ quality of life, health care resource use, and
related costs. Approximately 83,000 hospital episodes (including inpatient, day-case, and
intensive care episodes) were recorded as related to asthma in England in 2011–2012, repre-
senting approximately 3.3 million patients with clinician-reported, diagnosed-and-treated
asthma in England during that time [1].
Recent studies have demonstrated an association between high blood eosinophil counts
and greater risk of asthma exacerbations, especially in patients with asthma that is not well-
controlled [2,3]. Moreover, among patients with severe asthma in a US cohort study, the odds
of asthma-related hospital admissions were significantly greater for patients with high blood
eosinophil count defined as0.4x109 cells/L than for those with counts of<0.4x109 cells/L
[4]. Similarly, in the UK, patients with severe uncontrolled eosinophilic asthma (blood eosino-
phil count0.3x109 cells/L) experienced over 7 times the number of hospitalizations per year
compared with the general asthma population [5], and in Finland, a blood eosinophil count
>0.3x109 cells/L was associated with 13% greater rate of hospital admissions (vs.0.3x109
cells/L) among patients with asthma [6]. Targeted therapy for patients with severe eosinophilic
asthma can reduce the rate of exacerbations requiring hospitalization and/or an emergency
department (ED) visit [7,8].
Patients who are admitted to hospital for asthma-related reasons, such as a severe exacerba-
tion, may be at risk of short-term readmission to hospital. For example, some patients with
persistent airways inflammation are at risk of readmission after discharge despite treatment
with corticosteroids [9,10]. Predictors of readmission are important to identify as this informa-
tion could be used to improve in-hospital and post-hospitalization patient management to
minimize subsequent readmissions. Several demographic and socioeconomic risk factors for
hospital readmissions have been reported for patients with asthma, including older age, greater
number of comorbidities, an urban hospital setting, and longer length of hospital stay [11,12].
A recent study found that elevated blood eosinophil count (0.3x109 cells/L) in the first blood
sample upon hospitalization was associated with a lower incidence of hospital readmissions as
compared with an eosinophil count<0.3x109 cells/L [13]. Conversely, for patients with
chronic obstructive pulmonary disease (COPD), a recent publication reports an association of
increased readmissions with blood eosinophil count0.20x109 cells/L at first hospitalization
[14]. The variability in associations may be because blood eosinophils are prognostic and
theragnostic.
The aim of this study was to determine if patients hospitalized for an asthma exacerbation
were more likely to be readmitted if their preadmission blood eosinophil count was elevated.
Our hypothesis was that standard management of asthma exacerbations is insufficient to pre-
vent readmissions for patients who have high blood eosinophil counts in the year preceding a
hospitalization.
Blood eosinophil count and risk of readmission for asthma
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Methods
Data source
We used primary and secondary care data from the Clinical Practice Research Datalink
(CPRD) and linked Hospital Episode Statistics (HES) for this historical cohort study of
patients with asthma who had been admitted to hospital in England. The CPRD is a large well-
validated database, frequently used for medical and health research, that contains de-identi-
fied, longitudinal medical records of 5 million patients from >600 UK practices [15]. The
linked HES data include detailed information about hospital admissions, ED visits, and outpa-
tient visits to secondary care in England [16]. We used the HES Admitted Patient Care data-
base, which contains records of patients who were admitted to a hospital ward, including
patients who visited an ED before admission and those who were admitted to an intensive care
unit. Diagnostic and treatment data are recorded in the CPRD using Read codes, while diagno-
sis data are recorded in HES using International Classification of Disease (ICD)-10 clinical
coding and OPCS4 procedural coding.
The study dataset spanned the period from April 1997 through February 2016.
Study design and patients
Eligible patients were 5 years or older at the time of their most recent asthma diagnosis and
had active asthma, which we defined as (1) a diagnostic Read code for asthma qualifying for
inclusion in the asthma registry, which general practices in the UK maintain for the Quality
Outcomes Framework (QOF) [17], (2) no recorded asthma-resolved Read code after the last
asthma diagnosis code, and (3) at least 2 prescriptions for asthma (controller or reliever medi-
cation) during 1 baseline year. Patients admitted to hospital with asthma as the primary diag-
nosis (ICD-10 code J45-J46) were eligible for the study if they had one or more valid blood
eosinophil counts recorded during the year before the hospital admission with no prescription
for oral corticosteroids within 2 weeks before the eosinophil count.
Eligible patients had to have available, continuous data throughout the study period (Fig 1),
which included1 baseline year before discharge from the hospital for patient characteriza-
tion and1 outcome year after hospital discharge for follow-up (except for patients who died
within 1 year after hospital discharge). We included the first hospitalization recorded for each
patient meeting those criteria. A diagnostic Read code for any of the following chronic respira-
tory conditions recorded at any time was cause for exclusion from the study: bronchiectasis,
pulmonary sarcoidosis, hypersensitivity pneumonitis, malignancy of the lungs, interstitial lung
disease, and cystic fibrosis. Patients with concomitant diagnosis of COPD were not excluded.
The study was performed in compliance with all applicable local and international laws and
regulations and to standards suggested for observational studies, including an independent
advisory group, use of an a priori analysis plan, and study registration with commitment to
publish [18]. The study protocol was approved by the CPRD Independent Scientific Advisory
Committee (ISAC approval number 16_236) and registered with the European Union elec-
tronic Register of Post-Authorisation Studies (EU PAS Register number EUPAS15869) [19].
No patient identifying information was accessible during the study.
Outcome assessments
The exposure of interest was the most recent blood eosinophil count measured within 1 year
before hospital admission. For patients who had multiple tests in the baseline year, we used the
blood eosinophil count (with no oral corticosteroid prescription within 2 weeks prior) that
was closest to the admission. A high blood eosinophil count was defined as0.35x109 cells/L
Blood eosinophil count and risk of readmission for asthma
PLOS ONE | https://doi.org/10.1371/journal.pone.0201143 July 25, 2018 3 / 15
support from GSK, grants and personal fees from
Novartis, non-financial support from Nutricia,
personal fees from Pfizer, outside the submitted
work.JWHK reports grants and personal fees from
AstraZeneca, grants and personal fees from
Boehringer Ingelheim, grants from Chiesi, grants
and personal fees from GSK, grants and personal
fees from Novartis, grants from Mundi Pharma,
grants from TEVA, outside the submitted work.
AMG has attended advisory boards for Glaxo
SmithKline, Novartis, AstraZeneca, Boehringer
Ingelheim andTeva. He has received speaker fees
from Novartis, AstraZeneca, Vectura, Boehringer
Ingelheim and Teva. He has participated in
research with Hoffman La Roche, GlaxoSmithKline
and Boehringer Ingelheim. He has attended
international conferences sponsored by
AstraZeneca and Boehringer Ingelheim. He has
consultancy agreements with AstraZeneca and
Vectura. IDP has received speaker’s honoraria for
speaking at sponsored meetings from
AstraZeneca, Boehringer Inglehiem, Aerocrine,
Almirall, Novartis, and GSK and a payment for
organising an educational event for SPRs from AZ.
He has received honoraria for attending advisory
panels with Almirall, Genentech, Regeneron,
AstraZeneca, Boehringer Ingelheim, GSK, MSD,
Schering-Plough, Novartis, Dey, Napp and
Respivert. He has received sponsorship to attend
international scientific meetings from Boehringer
Ingelheim, GSK, AstraZeneca and Napp. DBP has
board membership with Aerocrine, Amgen,
AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan,
Mundipharma, Napp, Novartis, and Teva
Pharmaceuticals; consultancy agreements with
Almirall, Amgen, AstraZeneca, Boehringer
Ingelheim, Chiesi, GlaxoSmithKline, Mylan,
Mundipharma, Napp, Novartis, Pfizer, Teva
Pharmaceuticals, and Theravance; grants and
unrestricted funding for investigator-initiated
studies (conducted through Observational and
Pragmatic Research Institute Pte Ltd) from
Aerocrine, AKL Research and Development Ltd,
AstraZeneca, Boehringer Ingelheim, British Lung
Foundation, Chiesi, Mylan, Mundipharma, Napp,
Novartis, Pfizer, Respiratory Effectiveness Group,
Teva Pharmaceuticals, Theravance, UK National
Health Service, Zentiva; payment for lectures/
speaking engagements from Almirall, AstraZeneca,
Boehringer Ingelheim, Chiesi, Cipla,
GlaxoSmithKline, Kyorin, Mylan, Merck,
Mundipharma, Novartis, Pfizer, Skyepharma, and
Teva Pharmaceuticals; payment for manuscript
preparation from Mundipharma and Teva
Pharmaceuticals; payment for the development of
educational materials from Mundipharma and
Novartis; payment for travel/accommodation/
(or0.4x109 cells/L when counts were recorded to only 1 decimal place). This value was cho-
sen based on our findings in a prior study in which patients with blood eosinophil counts
>0.3x109 cells/L experienced more severe exacerbations and poorer asthma control [3].
The primary outcome was readmission to hospital with asthma as primary diagnosis (ICD-
10 code J45/J46) over a 4-week outcome period and over a 1-year outcome period after dis-
charge from the hospital (Fig 1). The secondary outcome was readmission to hospital with
asthma as a secondary/subsidiary diagnosis and a respiratory condition as primary diagnosis
(ICD-10 codes J00-J99), again observed over 4 weeks and 1 year.
Statistical analysis
Patients’ baseline characteristics and hospital readmissions were compared between patients
with high and normal blood eosinophil counts using Pearson’s χ2 test of independent catego-
ries for categorical variables, and the Mann-Whitney test for continuous variables.
Kaplan-Meier curves were constructed for patients with and without high blood eosinophil
count for the maximum follow-up period of 1 year after hospital discharge. Comparisons were
made with log-rank analyses, and patients were censored if they died.
Cox proportional hazard regression, with the time from hospital discharge date to the first
readmission date as the “survival” time, was performed to estimate hazard ratios (HRs) with
95% confidence intervals (CIs) for the association between high blood eosinophil count and
time to readmission, adjusted for potential confounders. The following variables were evalu-
ated for their potential confounding effect on the effect estimate: sex, age, body mass index
(BMI), smoking habits, timing of blood eosinophil count relative to the first hospitalization,
Charlson comorbidity index (categorical as 0, 1−4,5), comorbidities, and Global Initiative
for Asthma [20] (GINA) treatment step (S1 Table). The likelihood of a blood eosinophil count
being recorded was greater at dates closer to the hospital admission, and we included the time
between recorded eosinophil count and first hospitalization as a confounder in the Cox regres-
sion model. Final models were arrived at following a forward-selection procedure, in which
variables were added one-by-one and retained if the coefficient for the effect estimate (high
eosinophil count) changed by5%. Co-linearity was checked by evaluating variance inflation
factors, which were all under 5%. The validity of the proportional hazards assumption was
checked by examination of survival curves, and p-values were calculated using a Wald test.
Potential effect modification of smoking status was tested for significance by including an
interaction term into the full model. We conducted several sensitivity analyses, repeating the
outcome analyses using alternative definitions of high blood eosinophil counts (0.25x109
cells/L or0.3x109 cells/L if rounded, and0.45x109 cells/L or0.5x109 cells/L if rounded)
and examining outcomes in two subsets of patients: (1) after exclusion of those who initiated
inhaled corticosteroids (ICS) after their first asthma-related hospital admission and (2) after
exclusion of patients with a concomitant diagnosis of COPD.
Statistical analyses were conducted using IBM SPSS Statistics version 23 (IBM SPSS Statis-
tics, Feltham, Middlesex, UK) and R version 3.0.2 (The R Project for Statistical Computing;
https://www.r-project.org/). A statistically significant result was defined as p0.05.
Results
Patients
Of 146,485 patients in the CPRD with HES data linkage, 22,940 (16%) patients had at least one
hospital admission for asthma and2 years of medical record data, and 3,611 patients (16%)
of those hospitalized had an eosinophil count recorded within 1 year before the hospitalization
Blood eosinophil count and risk of readmission for asthma
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(and no oral corticosteroid prescription within 2 weeks prior). Of these 3,611 patients, 2,613
patients (72%) were5 years old, had active asthma, and were eligible for the study (Fig 2).
In the study population, 482 of 2,613 patients (18%) were discharged from hospital on the
same day. Six patients died (one patient died 31 weeks after readmission for asthma and was
not censored; others were censored) during 1 year of follow up.
Characteristics of the total population with blood eosinophil count (n = 2,613) and 13,016
patients with asthma who met all eligibility criteria except availability of blood eosinophil
count during baseline are presented in S2 Table. There were multiple statistically significant
differences between the two groups of patients. Eligible patients with recorded eosinophil
count were older than the 13,016 patients without eosinophil count (median age, 50 vs. 33
years), more commonly female (1,997/2,613, 76% vs. 7,542/13,016, 58%), heavier (mean BMI
29.1 vs. 26.0 kg/m2), and receiving a higher median ICS dose (219 vs. 132 μg/day, fluticasone-
propionate equivalent) during the baseline year (S2 Table).
A high blood eosinophil count (0.35x109 cells/L) was recorded during the year before the
hospital admission for 835 of 2,613 patients (32%). The high blood eosinophil cohort had a
median age of 45 (vs. 54 years in the cohort with eosinophil count of<0.35x109 cells/L) and
included proportionately fewer women and fewer overweight and obese patients (Table 1). In
addition, patients with eosinophil count0.35x109 cells/L were more likely to be never-smok-
ers and to have a recorded diagnosis of rhinitis, atopic eczema, or nasal polyps.
The likelihood of a blood eosinophil count being recorded was greater at dates closer to the
hospital admission (S1 Fig). Patients with measurements within 4 weeks before the hospitaliza-
tion were more likely to have a high blood eosinophil count (128/339, 38%) than those with
measurement within a longer time period before the hospitalization (707/2274, 31%;
p = 0.014). The length of time between recorded eosinophil count and admission with asthma
as the primary diagnosis was greater in patients with high blood eosinophil counts than in
Fig 1. Study design.
https://doi.org/10.1371/journal.pone.0201143.g001
Blood eosinophil count and risk of readmission for asthma
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patients without high counts, but the difference in distribution was not statistically significant
(144 days [IQR, 56−250] vs. 131 days [58−229], p = 0.159).
The median duration of hospitalization (2 nights) was the same in patients with and with-
out a high blood eosinophil count; however, there were fewer patients with a high blood eosin-
ophil count who had a long hospital stay (Table 2).
Fig 2. Flow diagram showing selection of eligible patients from the database. CPRD = Clinical Practice Research Database.
HES = Hospital Episode Statistics. OCS = oral corticosteroid. QOF = Quality Outcomes Framework.
https://doi.org/10.1371/journal.pone.0201143.g002
Blood eosinophil count and risk of readmission for asthma
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Table 1. Baseline demographic and clinical characteristics.
All patients
(N = 2,613)
Blood eosinophil cohort
Variable <0.35x109 cells/L
(n = 1,778)
0.35x109 cells/L
(n = 835)
P valuea
Age
Median (IQR) 51.0 (36.0–69.0) 54.0 (39.0–70.3) 45.0 (30.0–65.0) <0.0001
5–12 years 56 (2.1) 17 (1.0) 39 (4.7) <0.0001
13–17 years 77 (2.9) 31 (1.7) 46 (5.5)
18–64 years 1,681 (64.3) 1,141 (64.2) 540 (64.7)
65 years 799 (30.6) 589 (33.1) 210 (25.1)
Female sex 1,997 (75.7) 1,392 (78.3) 585 (70.1) <0.0001
Smoking statusb
Data available 2,597 (99.4) 1,771 (99.6) 826 (98.9)
Current smoker 547 (21.1) 378 (21.3) 169 (20.5) 0.007
Ex-smoker 754 (29.0) 544 (30.7) 210 (25.4)
Never smoker 1,296 (49.9) 849 (47.9) 447 (54.1)
Body mass indexb
Data available 2,260 (86.5) 1,551 (87.2) 709 (84.9)
Mean (SD) 29.2 (7.0) 29.6 (7.0) 28.4 (7.0) <0.0001
<18.5 kg/m2 78 (3.5) 38 (2.5) 40 (5.6) <0.0001
18.5 kg/m2 to <25 kg/m2 625 (27.7) 393 (25.3) 232 (32.7)
25 kg/m2 to <30 kg/m2 625 (27.7) 450 (29.0) 175 (24.7)
30 kg/m2 932 (41.2) 670 (43.2) 262 (37.0)
Allergic/non-allergic rhinitisc 876 (33.5) 545 (30.7) 331 (39.6) <0.0001
Atopic eczemac 927 (35.5) 595 (33.5) 332 (39.8) <0.0001
Nasal polypsc 83 (3.2) 39 (2.2) 44 (5.3) <0.0001
Chronic rhinosinusitisc 579 (22.2) 400 (22.5) 179 (21.4) 0.54
COPDc 284 (10.9) 192 (10.8) 92 (11.0) 0.87
GERDc 474 (18.1) 355 (20.0) 119 (14.3) <0.001
Cardiovascular diseasec 654 (25.0) 491 (27.6) 163 (19.5) <0.0001
Charlson comorbidity index
0 611 (23.4) 429 (24.1) 182 (21.8) 0.028
1–4 1,661 (63.6) 1,101 (61.9) 560 (67.1)
5 341 (13.1) 248 (13.9) 93 (11.1)
GINA step of asthma treatmentb
1 124 (4.7) 78 (4.4) 46 (5.5) 0.009
2 493 (18.9) 357 (20.1) 136 (16.3)
3 468 (17.9) 298 (16.8) 170 (20.4)
4 1,220 (46.7) 848 (47.7) 372 (44.6)
5 308 (11.8) 197 (11.1) 111 (13.3)
1 ICS inhaler prescribed 2,444 (93.5) 1,671 (94.0) 773 (92.6) 0.173
Daily dose of ICS (μg/day), median (IQR)d 262 (110–521) 263 (110–534) 247 (99–492) 0.041
1 SABA inhaler prescribed 2,432 (93.1) 1,646 (92.6) 786 (94.1) 0.144
Daily SABA dose, median (IQR)d 1.64 (0.82–3.55) 1.64 (0.66–3.29) 2.04 (0.82–4.11) <0.0001
OCS daily dose (g), median (IQR) 0.55 (0–1.64) 0.55 (0–1.56) 0.55 (0–1.75) 0.139
No. severe asthma exacerbations
(Continued)
Blood eosinophil count and risk of readmission for asthma
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Readmissions by eosinophil cohort
Only 6 patients were readmitted to the hospital within 4 weeks of the first admission, with no
significant difference between blood eosinophil cohorts (Table 3). At 1 year, 130 of 2,613 (5%)
patients overall were readmitted for asthma, including a significantly greater percentage of
patients with high vs. normal blood eosinophil count (Table 3; Fig 3). Patients with eosinophil
count of0.35x109 cells/L had a 49% higher adjusted risk of readmission to hospital for
asthma in the first year of follow-up than patients without a high count (HR 1.49; 95% CI
1.04–2.13; p = 0.029; Table 3).
Interaction with smoking status
The effect of current smoking was non-significant (p = 0.073) when tested by including an
interaction term for current smoking (yes/no) and high blood eosinophil count (yes/no) into
Table 1. (Continued)
All patients
(N = 2,613)
Blood eosinophil cohort
Variable <0.35x109 cells/L
(n = 1,778)
0.35x109 cells/L
(n = 835)
P valuea
0 747 (28.6) 516 (29.0) 231 (27.7) 0.25
1 848 (32.5) 589 (33.1) 259 (31.0)
2 506 (19.4) 345 (19.4) 161 (19.3)
3 266 (10.2) 174 (9.8) 92 (11.0)
4 246 (9.4) 154 (8.7) 92 (11.0)
Data expressed as No. (%) unless otherwise noted. COPD = chronic obstructive pulmonary disease. GERD = gastroesophageal reflux disease. GINA = Global Initiative
for Asthma; ICS = inhaled corticosteroid; OCS = oral corticosteroid; SABA = short-acting β-agonist.
aP-value comparing blood eosinophil cohorts, computed from χ2 test for categorical variables, or Mann-Whitney test, for continuous variables. Where variables are
presented as both continuous and categorical, the p-value is from the Mann-Whitney test.
bThe closest BMI within 10 years of hospital discharge, and the smoking status closest to and within 5 years before hospital discharge, were included. The GINA
treatment step was determined based on the last prescription before the hospitalization (S1 Table). The BMI categories applied to patients18 years old; for children,
BMI was not calculated because accurate information on age in months required to calculate BMI z-scores was not provided for privacy reasons.
cComorbidities were those with diagnostic Read code ever-recorded in the available data before hospital discharge.
dICS dose expressed as fluticasone propionate equivalent (μg/day), and one SABA dose defined as 200 μg in albuterol equivalents.
https://doi.org/10.1371/journal.pone.0201143.t001
Table 2. Duration of hospitalization.
All patients
(N = 2,613)
Blood eosinophil cohort
Variable <0.35x109 cells/L
(n = 1,778)
0.35x109 cells/L
(n = 835)
P valuea
Nights in hospital, median (IQR) 2 (1–5) 2 (1–4)
No. nights in hospital, n (%)
0 482 (18.4) 323 (18.2) 159 (19.0) 0.006
1 529 (20.2) 349 (19.6) 180 (21.6)
2 356 (13.6) 230 (12.9) 126 (15.1)
3 281 (10.8) 182 (10.2) 99 (11.9)
4 243 (9.3) 162 (9.1) 81 (9.7)
5 149 (5.7) 99 (5.6) 50 (6.0)
6 142 (5.4) 106 (6.0) 36 (4.3)
7 431 (16.5) 327 (18.4) 104 (12.5)
aP-value comparing blood eosinophil cohorts computed from χ2 test.
https://doi.org/10.1371/journal.pone.0201143.t002
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Table 3. Readmissions to hospital within 4 weeks and 1 year and hazard ratios for readmission in the high eosinophil count cohort.
Eosinophil cohort
Readmission <0.35x109
cells/L
(n = 1,778)
0.35x109
cells/L
(n = 835)
P
valuea
Adjusted HR (95% CI) for blood eosinophil
count0.35x109/Lb
P
value
With asthma as primary diagnosis (n = 2,613)
Within 4 weeks 4 (0.2) 2 (0.2) 0.94 — —
Within 1 year 75 (4.2) 55 (6.6) 0.009 1.49 (1.04–2.13) 0.029
By known smoking status (n = 2,597)c
Never-smokers (n = 1,296) 29 (3.4) 30 (6.7) 0.007 2.16 (1.27–3.68) 0.005
Ex-smokers (n = 754) 19 (3.5) 13 (6.2) 0.010 1.49 (0.73–3.06) 0.27
Current smokers (n = 547) 27 (7.1) 12 (7.1) 0.99 1.00 (0.49–2.04) 0.997
Never/ex-smokers pooled (n = 2,050) 48 (3.4) 43 (6.5) 0.002 1.78 (1.17–2.73) 0.007
With respiratory condition other than asthma, and asthma as
subsidiary diagnosis (n = 2,613)
Within 4 weeks 22 (1.2) 8 (1.0) 0.53 — —
Within 1 year 81 (4.6) 39 (4.7) 0.90 1.12 (0.76–1.65) 0.57
aP-value computed using χ2 test.
bAdjusted for sex, age, smoking status, timing of blood eosinophil count measurement, duration of index hospitalization.
c16 patients with no recent record of smoking status were excluded from the analyses by smoking status.
https://doi.org/10.1371/journal.pone.0201143.t003
Fig 3. Kaplan-Meier curves describing the cumulative “survival” of a readmission to hospital for asthma in the
first year after an admission with asthma as the primary diagnosis in patients with and without high blood
eosinophil count.
https://doi.org/10.1371/journal.pone.0201143.g003
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the model. The increased readmission rate with a high blood eosinophil count was found only
in non-smokers (HR 1.84; 1.20–2.80; p = 0.005) and not in current smokers (HR 0.88; 0.44–
1.76; p = 0.73). In this analysis of all 2,613 patients, 16 patients without recent, recorded smok-
ing status were included as non-smokers (never-smokers plus ex-smokers).
Results were similar for patients with known smoking status, with a significant 216% higher
adjusted risk of readmission for never-smokers with high blood eosinophil count, and no addi-
tional risk for current smokers with high blood eosinophil count (Table 3). Although the asso-
ciation was most pronounced in never-smokers, no significant difference in the association
was found between never-smokers and ex-smokers (p = 0.67) in the 2,050 patients recorded as
not currently smoking.
Sensitivity analyses
A high blood eosinophil count was recorded for 1,328 patients (51%) when defined as
0.25x109 cells/L, and for 588 patients (23%) when defined as0.45x109 cells/L. The associa-
tion between a high blood eosinophil count and readmission to hospital for asthma was less
pronounced and not significant for patients with blood eosinophil count of either0.25x109
cells/L (HR = 1.17; 0.82−1.66; p = 0.39) or0.45x109 cells/L (HR = 1.15; 0.77−1.72; p = 0.50;
S3 Table). The association was also not significant in never-smokers or in never/ex-smokers
combined using either definition of high blood eosinophil count (S3 Table).
A total of 169 of the 2,613 patients (6%) had no prescription for ICS in the baseline year
before being hospitalized for asthma; of the 169, 115 (68%) had ICS prescribed in the outcome
year. After exclusion of these 115 patients, HRs for the association with blood eosinophil count
of0.35x109 cells/L slightly increased as compared with those for the full population (S3
Table). The HR was 1.77 (95% CI, 1.15−2.72; p = 0.009) for never/ex-smokers combined,
which was very similar to the HR for never/ex-smokers combined of the full population (1.78).
However, effect modification by current smokers was not significant in this subpopulation
(p = 0.28).
Results of an additional subanalysis excluding patients with a concomitant diagnosis of
COPD showed no relevant difference in association for the remaining 2,329 patients
(HR = 1.48; 95% CI 1.01–2.17, p = 0.045; see S3 Table).
Discussion
In this large, historical cohort study, we found that patients who had a blood eosinophil count
of0.35x109 cells/L recorded in the year preceding an asthma-related hospitalization had a
significantly greater risk of readmission for asthma during the year after they were discharged.
Few patients (n = 6) were readmitted to hospital for asthma within 4 weeks after discharge,
while by 1 year after discharge, 5% (130 of 2,613) patients were readmitted for asthma. The
greater risk of readmission during 1 year follow-up was present only for patients with high
blood eosinophil count who were never- or ex-smokers (not for current smokers).
Our study is one of few studies examining hospital readmissions for asthma in a general
asthma population and in the real-life setting. Readmissions in the present study were compar-
atively infrequent relative to results in other studies: for example, in one US study, approxi-
mately 4% of patients were readmitted for an asthma exacerbation within 30 days [21], and in
France from 2002–2005, 15% were readmitted for asthma within 1 year [22]. The overall rate
of hospital admissions for asthma in England appears to be lower that than for Western
Europe as a whole, the latter reported in 2004 to be 7% [1,23].
Other recent studies of hospital readmissions have been limited to patients on systemic cor-
ticosteroids [9], have examined readmissions up to only 30 days [11,12,24], were much smaller
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[24], and/or were conducted at a single institution [25,26]. None of these studies, nor others
examining readmissions after 30 days [27–29], examined the association of hospital readmis-
sions with blood eosinophil count. While Gonzalez-Barcala et al. [13] in their retrospective
study at a single hospital in Spain found differently from the present study that elevated eosin-
ophil count was associated with a lower incidence of readmissions, it is difficult to compare
their study with ours because of differences in methods. For example, the reference blood
eosinophil count was that taken upon admission rather than before hospitalization during a
baseline year, and the length of the follow-up period for analyzing readmissions is unclear
[13].
An interesting finding in the present study that requires further investigation is the effect of
smoking status on association of readmissions with eosinophil count. Cigarette smoking
increases levels of oxidative stress, alters airway immune responses, and increases risk of hospi-
talization in patients with asthma [30]. Westerhof et al. [31] in their study of patients with
severe asthma found that frequent exacerbations were associated with blood eosinophil count
only in never smokers and not in ex-smokers, for whom blood neutrophil count was an inde-
pendent predictor of frequent exacerbations (smokers not studied). In our study, both never-
and ex-smokers (but not current smokers) who had a high eosinophil count were at greater
risk of asthma-related readmission, although for ex-smokers separately this association was
not statistically significant. Moreover, in our study the difference in association between non-
smokers (never-plus ex-smokers pooled) and smokers was large and statistically significant.
Clearly, additional work is needed to examine biomarker and peripheral blood cell profiles in
relation to smoking status and hospital readmissions and other asthma-related outcomes.
The median duration of hospitalization (2 nights) was the same in both normal and high
blood eosinophil cohorts; however, patients with a high blood eosinophil count were less likely
to have a hospital stay longer than 5 nights (17% vs. 24% of those without high eosinophil
count). This finding illustrates the conundrum of eosinophilic asthma: while it tends to be
more severe in terms of exacerbations and asthma control, eosinophilic asthma is also poten-
tially more responsive to therapies targeting type 2 inflammation, including ICS and biologics.
We speculated that the association between eosinophil count and readmission could be
diluted for patients with eosinophil count performed several months before the first admis-
sion; therefore, we re-examined outcomes including only patients with eosinophil counts mea-
sured close to the initial hospitalization to see if the association were stronger. However, when
selecting those with eosinophil count recorded within 4 months before hospitalization, the
numbers became small and associations non-significant, although the direction of the effect
was the same: for never- and ex-smokers pooled (n = 915), the risk of readmission was 51%
greater but non-significant (adjusted HR 1.69;0.60–4.76; p = 0.32).
A strength of this study is that we included a broad patient population with asthma, not lim-
ited to those with severe asthma. We selected inclusion criteria to ensure that patients’ asthma
was actively managed in advance of the hospital admission, thereby excluding patients
experiencing a first episode of asthma diagnosed at the time of admission. Moreover, we
required that patients had not received an oral corticosteroid prescription within 2 weeks
before the eosinophil count to obviate the eosinopenic effects of systemic corticosteroids
[32,33]. The data sources we used are well-regarded and frequently employed for pharmacoe-
pidemiological studies [15–17,34]. The primary care data in the CPRD is considered to be
high-quality, with recording that has been standardized and improved since the institution in
2004 of the UK Quality Outcomes Framework (QOF) [17], which provides financial incentives
for GPs to deliver quality care, including an annual asthma review covering asthma control sta-
tus, smoking, and inhaler technique. Detailed information about hospital admissions was
drawn from HES, a data warehouse linked to the CPRD [16].
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Nevertheless, a limitation is that the study dataset comprised information collected for clin-
ical and routine use rather than specifically for research purposes. Moreover, prescriptions for
drugs prescribed by specialists are not reliably recorded in the CPRD. Therefore, we could not
evaluate treatment prescribed immediately after hospital discharge. However, the daily dose of
ICS prescribed by GPs in the year after admission was not significantly different between
patients with and without high eosinophil counts (median for both: 329 vs. 329 μg/day flutica-
sone-equivalent, p = 0.70, Mann-Whitney test). Finally, as for all observational studies, there is
the possibility of residual confounding from unrecognized and/or unmeasured factors.
A “count-response” association of blood eosinophil levels with risk of asthma exacerbations
has been reported in both an observational study [3] and for the placebo arm of clinical trials
[35,36]. Our study had insufficient patient numbers to assess the presence of a count-response
relationship with hospital readmissions using incremental categories to define high eosinophil
count. Our definition of0.35x109 cells/L for high blood eosinophil count captured a clear
association of high blood eosinophil count with risk of readmission, while there were fewer
patients, hence limited statistical power, to evaluate the higher cut-point of0.45x109 cells/L,
although the direction of the effect was the same. Alternatively, new ICS use or better ICS
adherence after the index hospitalization might have reduced the effect of elevated eosinophil
count; however, it would not be easy to quantify this possibility in the framework of a historical
cohort study, and in spite of this possibility we found a strong association at the0.35x109
cells/L definition.
We did not exclude patients with a concomitant diagnosis of COPD; therefore, approxi-
mately one-tenth of the study population appeared to have some form of physician-diagnosed
asthma-COPD overlap [37], although these patients were too few to analyze separately. How-
ever, the sensitivity analysis excluding these patients supported the findings for the full
population.
By necessity we were able to include only patients who had a recorded blood eosinophil count,
which is not routinely measured in clinical practice, a factor serving as a possible source of selec-
tion bias and thereby limiting the generalizability of our findings. There were large differences in
baseline characteristics between the patients with available eosinophil count and those without,
who tended to be younger; more likely female, a current smoker, and of normal weight; and less
likely having comorbidities such as rhinitis, chronic sinusitis, gastroesophageal reflux disease, and
cardiovascular disease. The age differences were expected because older people more frequently
have full blood counts available. Further work is needed to examine the use of blood eosinophil
count in the clinical assessment of the full spectrum of patients with asthma.
Tailoring asthma therapy using sputum eosinophil counts appears to be effective in reduc-
ing exacerbations, particularly for adults with frequent exacerbations [38]. Thus, blood eosino-
phil count, more practical to measure than sputum eosinophil count, could play a role in
tailoring asthma therapy with the goal of reducing exacerbations, hence potentially hospital
readmissions. Moreover, further research is needed to identify the mechanism(s) behind the
increased risk of readmission associated with high blood eosinophil count, such as possible
undertreatment with ICS or insufficient effectiveness of ICS. In addition, more specifically, a
re-examination is needed of the absence of association with readmissions and high blood
eosinophil count in current smokers, as there was limited statistical power in this subgroup of
patients, reflected by the wide confidence interval.
Conclusions
A high blood eosinophil count in the year before an asthma-related hospitalization is associ-
ated with increased risk of readmission within the following year. This risk was slightly greater
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in the subset of patients who were not new initiators of ICS treatment after their index hospital
admission, suggesting that this trait is only partially treatable with anti-inflammatory therapy.
This association was present only in non-smoking patients with high blood eosinophil count.
Our findings support the benefit of including a full blood count with differential as a routine
assessment in clinical practice for patients with not well-controlled asthma. Moreover, our
findings support the need for careful follow-up, with treatment optimization, after hospital dis-
charge for patients with asthma and preadmission high blood eosinophil count.
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